Abstract
In most mammals purine degradation ultimately leads to the formation of allantoin. Humans lack the enzyme uricase, which catalyzes the conversion of uric acid to allantoin. The resulting higher level of uric acid has been hypothesized to play a role as an antioxidant. Hyperuricaemia is usually an asymptomatic condition which is hypothesized to play a role in cardiovascular disease and hypertension. Some hyperuricaemic individuals develop gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals in joints. Over time, acute intermittent gouty arthritis can develop into a chronic condition with deposits of monosodium urate (MSU) crystals in joints and as tophi. The mechanisms by which MSU crystals lead to an acute inflammatory arthritis are under investigation and current knowledge is reviewed here. Treatment of gout includes management of acute flares with anti-inflammatory medications such as non-steroidal anti-inflammatory drugs or corticosteroids and long term management with urate-lowering therapy when indicated. Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed.
Keywords: Hyperuricaemia, gout, xanthine oxidase inhibitors, uricase
Current Pharmaceutical Design
Title: Overview of Hyperuricaemia and Gout
Volume: 11 Issue: 32
Author(s): D. Masseoud, K. Rott, R. Liu-Bryan and C. Agudelo
Affiliation:
Keywords: Hyperuricaemia, gout, xanthine oxidase inhibitors, uricase
Abstract: In most mammals purine degradation ultimately leads to the formation of allantoin. Humans lack the enzyme uricase, which catalyzes the conversion of uric acid to allantoin. The resulting higher level of uric acid has been hypothesized to play a role as an antioxidant. Hyperuricaemia is usually an asymptomatic condition which is hypothesized to play a role in cardiovascular disease and hypertension. Some hyperuricaemic individuals develop gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals in joints. Over time, acute intermittent gouty arthritis can develop into a chronic condition with deposits of monosodium urate (MSU) crystals in joints and as tophi. The mechanisms by which MSU crystals lead to an acute inflammatory arthritis are under investigation and current knowledge is reviewed here. Treatment of gout includes management of acute flares with anti-inflammatory medications such as non-steroidal anti-inflammatory drugs or corticosteroids and long term management with urate-lowering therapy when indicated. Future directions in the treatment of gout, in part guided by a better understanding of pathophysiology, are discussed.
Export Options
About this article
Cite this article as:
Masseoud D., Rott K., Liu-Bryan R. and Agudelo C., Overview of Hyperuricaemia and Gout, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913318
DOI https://dx.doi.org/10.2174/138161205774913318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Insights Into Inositol Isoforms, Mediterranean and Ketogenic Diets for Polycystic Ovary Syndrome: From Bench to Bedside
Current Pharmaceutical Design Snacks and Snacking: Impact on Health of the Consumers and Opportunities for its Improvement
Current Nutrition & Food Science Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Intratubular Renin-Angiotensin System in Hypertension
Current Hypertension Reviews Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Modulation of Eating by Central Catecholamine Systems
Current Drug Targets Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease: The Overlap Syndrome
Current Respiratory Medicine Reviews Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews Global Cardiovascular Risk Management in Primary Prevention
Current Vascular Pharmacology Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis
Current Vascular Pharmacology Biological, Geometric and Biomechanical Factors Influencing Abdominal Aortic Aneurysm Rupture Risk: A Comprehensive Review
Recent Patents on Medical Imaging Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Hepatic Effects of Duloxetine – III: Analysis of Hepatic Events Using External Data Sources
Current Drug Safety Sex-Genetic Interaction in the Risk for Cerebrovascular Disease
Current Medicinal Chemistry Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry